Dr. Orlowski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Boulevard
Unit 429
Houston, TX 77030Phone+1 713-794-3234Fax+1 713-563-5067- Is this information wrong?
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1994 - 1998
- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1991 - 1994
- Yale School of MedicineClass of 1991
- Columbia College / Columbia UniversityBA, Chemistry, Magna Cum Laude, 1979 - 1983
- Bronx High School of ScienceHigh School, 1976 - 1979
Certifications & Licensure
- FL State Medical License 2021 - Present
- AZ State Medical License 2022 - 2025
- GA State Medical License 2022 - 2025
- TX State Medical License 2007 - 2025
- WA State Medical License 2022 - 2025
- LA State Medical License 2022 - 2024
- TN State Medical License 2022 - 2024
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2008-2014
- Top Doctors:SE Texas Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2007-2013
Clinical Trials
- Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Start of enrollment: 2001 May 01
- Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Start of enrollment: 2011 Jul 01
- Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients Start of enrollment: 2012 Jun 20
- Join now to see all
Publications & Presentations
PubMed
- MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis.Xiaobin Wang, Yingqing Shi, Hua Shi, Xiaoyu Liu, Aijun Liao, Zhuogang Liu, Robert Z Orlowski, Rui Zhang, Huihan Wang> ;Journal of Experimental & Clinical Cancer Research. 2024 Mar 5
- Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX.Spencer, A., Moreau, P., Mateos, M., Goldschmidt, H., Suzuki, K., Levin, M., Sonneveld, P., Orlowski, R., Yoon, S., Usmani, S., Weisel, K., Reece, D., Ahmadi, T., Pei,...> ;Blood Advances. 2024 Jan 23
- 1 citationsBispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.Sun, F., Cheng, Y., Wanchai, V., Guo, W., Mery, D., Xu, H., Gai, D., Siegel, E., Bailey, C., Ashby, C., Al Hadidi, S., Schinke, C., Thanendrarajan, S., Ma, Y., Yi, Q.,...> ;Nature Communications. 2024 Jan 19
- Join now to see all
Journal Articles
- Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction DrugsKrina Patel, Rohtesh Mehta, Donna M Weber, Sheeba K Thomas, Nina Shah, Hans C Lee, Elisabet E Manasanch, Muzaffar H Qazilbash, Qaiser Bashir, Simrit Parmar, Robert Z O..., Nature
- Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191Sheeba K Thomas, Robert Z Orlowski, Hans C Lee, Clinical Cancer Research
Abstracts/Posters
- A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)Robert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible f...Robert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African AmericansRobert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Amyloidosis and Waldenstr_m Macroglobulinemia (Part 2 of a 2-Part Series)61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Longer Term Follow up of the  Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) w...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Outcome of Autologous Stem Cell Transplantation in Waldenström's Macroglobulinemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- Upfront Daratumumab Shows Survival Benefit in Combination for Transplant-Ineligible Multiple MyelomaSeptember 11th, 2021
- Asylia Announces Formation of Distinguished Scientific Advisory BoardJuly 22nd, 2021
- Hematologic Oncology | Current Concepts and Recent Advances in Oncology Part 2: Multiple MyelomaDecember 30th, 2020
- Join now to see all
Grant Support
- P3 - Targeting The HDM-2 E3 Ligase In Multiple MyelomaNational Cancer Institute2010–2011
- M. D. Anderson Cancer Center Spore In Multiple MyelomaNational Cancer Institute2010–2011
- Developmental Research ProgramNational Cancer Institute2010–2011
- Administrative Core FacilityNational Cancer Institute2010–2011
- Dual Proteasome And MAPK Inhibition In Cancer TherapyNational Cancer Institute2008
- Dual Proteasome And MAPK Inhibition In Cancer TherapyNational Cancer Institute2004–2008
- Sb-743971 In Patients With Non-HodgkinsNational Center For Research Resources2007
- Px-171-001-Phase I Study Of Escalating Doses Of Proteasome InhibitorNational Center For Research Resources2006–2007
- Bortezomib And Pegylated Liposomal Doxorubicin As Therapy For Multiple MyelomaNational Center For Research Resources2005–2007
- Evaluation Of PS-341 In PTS W/ Hematologic MalignanciesNational Center For Research Resources2000
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: